Amount Raised
$150 Million
Round Type
Post-IPO Equity
DallasBiotechnologyDescription
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), announced today that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of approximately $150 million, before deducting placement agent commissions and offering expenses. The PIPE was led by new investor, RA Capital Management, with participation from a large institutional investor, PBM Capital, RTW Investments, LP, Venrock Healthcare Capital Partners, TCGX, Acuta Capital Partners, Kynam Capital Management, LP, Octagon Capital, Invus, GordonMD® Global Investments LP, and B Group Capital.
Quick answer
Taysha Gene Therapies, Inc. raised $150 Million in a Post-IPO Equity round, dated August 14, 2023. Taysha Gene Therapies, Inc. is based in Dallas, Texas, United States.
- How much did Taysha Gene Therapies, Inc. raise?
- Taysha Gene Therapies, Inc. raised $150 Million in a Post-IPO Equity round on August 14, 2023.
- What does Taysha Gene Therapies, Inc. do?
- Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease.
- Where is Taysha Gene Therapies, Inc. based and how big is it?
- Taysha Gene Therapies, Inc. is based in Dallas, Texas, United States.
- Who are the decision-makers at Taysha Gene Therapies, Inc?
- Fundz holds 1 contact at Taysha Gene Therapies, Inc. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Taysha Gene Therapies, Inc. that raised within 45 days of this round, from Fundz verified event records.
- Deka Biosciences, Inc. raised $20M (Series B) on September 28, 2023.
- Hepion Pharmaceuticals raised $5M on September 28, 2023.
- Slope raised $30M (Funding Round) on September 28, 2023.
- Triastek raised $20M (Funding Round) on September 28, 2023.
- Trautec raised an undisclosed amount (Series B) on September 28, 2023.
- RedHill Biopharma Ltd raised $4M (Seed) on September 28, 2023.
Who to call at Taysha Gene Therapies, Inc., and when
A new round usually means Taysha Gene Therapies, Inc. is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Taysha Gene Therapies, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Taysha Gene Therapies, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Taysha Gene Therapies, Inc.. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Taysha Gene Therapies, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Taysha Gene Therapies, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.